RedHill Biopharma Ltd (RDHL)

[DorseyE]

[/RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary b]
GlobeNewswire GlobeNewswire•April 28, 2020
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies

---

H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor for gastric cancer; H. pylori affects approximately 35% of the U.S. population
---
https://finance.yahoo.com/news/redhill-biopharma-strengthens-coverage-talicia-110010706.html